I 
<> 
3 
4 
5 
G 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
20 
(A) an evaluation of the anticipated applica- 
tions of genetic manipulation technology to such 
areas as medicine, pharmacology, immunology, in- 
dustrial fermentation, and agriculture; [and] 
(B) a thorough consideration of the ethical, 
moral, social, economic, environmental, and political 
implications of the development and use of such 
[technology.] technology, as well as the signifi- 
cance of lessons learned through recombinant DNA 
research and its allied science policy issues; and 
(C) a comprehensive assessment of the status 
and applications, achieved or anticipated, of ge- 
netic manipulation technology in other nations 
engaged in such activities. 
Sec. 203. (a) The Commission shall in carrying out 
its duties under section 202 hold public hearings as ap- 
propriate. 
(b) The Commission may secure directly from any 
department or agency of the United States information neces- 
sary to enable it to carry out its duties. Upon the request of 
the Chairman of the Commission, the head of such depart- 
ment or agency shall furnish such information to the Com- 
mission. 
Sec. 204. (a) Uot later than eighteen months after the 
date of the enactment of this Act, the [Secretary] Commis- 
[Appendix B — 240] 
